Teva Investment Highlights Investment Attractiveness For Drugmakers

Israel-based generic drugmaker Teva is to invest over EUR65mn (US$93mn) in a new manufacturing plant in Hungary. The Israeli firm's 15,000 square-metre plant, to be located in Gödöllő, near Budapest, will produce eye drops, syringes and other sterile products. Initial production is scheduled for launch in Q311, with the plant becoming fully operational by end-2014. Upon completion, Teva's sterile manufacturing output will be doubled, with products destined for the domestic, European and US

To read the full article, please choose one of the following options: